Company Overview
Terns Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical company dedicated to developing small-molecule product candidates designed for the treatment of oncology and obesity. The company is actively advancing TERN-701, an allosteric BCR-ABL tyrosine kinase inhibitor, which is currently in a Phase 1 clinical trial for the treatment of chronic myeloid leukemia. This entity functions within the Healthcare sector and specifically within the Biotechnology industry, distinguishing it from large-cap pharmaceutical firms that typically possess established commercial product portfolios. The company's scale is defined by a market capitalization of $5.34B, supported by a workforce of 59 employees, while reported revenue and annual sales figures are not available in the current data set. The absence of disclosed revenue data alongside a substantial market capitalization suggests that the company's valuation is driven primarily by potential future clinical outcomes and intellectual property assets rather than current commercial earnings.
Financial Health
The financial statements for Terns Pharmaceuticals, Inc. reflect a pre-revenue or early-stage commercial profile, with Revenue (TTM) listed as N/A and a Net Income (TTM) of $-94,435,000. The EBITDA stands at $-108,331,000, and the significant negative net income relative to the reported zero revenue indicates a cost structure dominated by research, development, and clinical trial expenditures rather than cost of goods sold. Free Cash Flow is reported at $-51,270,876, which signifies that the company is currently consuming cash reserves to fund its operational and clinical activities rather than generating liquidity from operations. All three margin metrics—Gross Margin, Operating Margin, and Profit Margin—are recorded at 0.0%, a common characteristic for biotechnology entities in the clinical stage where revenue has not yet materialized to offset substantial operating costs. The company holds $295.64M in cash against a minimal debt load of $1.03M, resulting in a Debt to Equity ratio of 0.36. This balance sheet composition indicates a highly conservative capital structure with negligible leverage, as the debt obligation is virtually insignificant compared to the available cash reserves. Furthermore, the Current Ratio is 19.52, an exceptionally high figure that demonstrates robust short-term liquidity and an overwhelming ability to meet immediate obligations without relying on external financing. Return on Equity is -29.1% and Return on Assets is -19.9%, metrics that mathematically reflect the heavy investment phase of the business model where assets are deployed to generate future value rather than current returns.
Valuation Assessment
Valuation multiples for Terns Pharmaceuticals, Inc. present a complex picture due to the lack of positive earnings history, with the P/E Ratio (TTM) listed as N/A and the Forward P/E standing at -39.56. The negative forward P/E ratio implies that analysts or data providers are projecting continued negative earnings in the near term, preventing the calculation of a traditional price-to-earnings multiple based on expected profitability. The Price to Book ratio is 15.11, which indicates that the market is pricing the company at a significant premium over its book value, reflecting high expectations for the success of its clinical pipeline and asset potential. Alternative valuation metrics such as the Price to Sales ratio, which is N/A, and the EV/EBITDA of -38.08, further underscore that traditional profitability-based valuation models are not applicable to this clinical-stage entity. The stock's price volatility is characterized by a 52-week high of $49.53 and a 52-week low of $1.86, illustrating an extremely wide trading range typical of small-cap biotechnology stocks. The Beta of -0.29 is a negative value, suggesting that the stock price has historically moved inversely to the broader market or displayed volatility patterns that diverge from standard beta coefficients.
Growth & Income
Growth metrics for Terns Pharmaceuticals, Inc. are reported as N/A for both Revenue Growth (YoY) and Earnings Growth (YoY), as the company has not yet generated sufficient revenue to calculate year-over-year expansion rates. The absence of positive earnings growth or revenue growth data implies that the company is in a capital-intensive development phase where financial resources are directed toward product advancement rather than scaling commercial sales. Regarding income generation, the company does not pay dividends, evidenced by a Dividend Yield of N/A and a Payout Ratio of 0.0%. Consequently, the company reinvests all available earnings and cash flow back into research, development, and clinical trials rather than distributing income to shareholders. The overall growth and income profile is defined by a complete reliance on external capital markets and internal cash reserves to fund operations, with no current distribution of returns to investors.